During the last session, Kazia Therapeutics Limited ADR (NASDAQ:KZIA)’s traded shares were 3.5 million, with the beta value of the company hitting 2.18. At the end of the trading day, the stock’s price was $0.53, reflecting an intraday loss of -11.48% or -$0.06. The 52-week high for the KZIA share is $1.58, that puts it down -198.11 from that peak though still a striking 64.15% gain since the share price plummeted to a 52-week low of $0.19. The company’s market capitalization is $12.41M, and the average intraday trading volume over the past 10 days was 77.48 million shares, and the average trade volume was 12.60 million shares over the past three months.
Kazia Therapeutics Limited ADR (KZIA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. KZIA has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Kazia Therapeutics Limited ADR (NASDAQ:KZIA) trade information
Kazia Therapeutics Limited ADR (KZIA) registered a -11.48% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -11.48% in intraday trading to $0.53, hitting a weekly high. The stock’s 5-day price performance is -41.38%, and it has moved by 117.79% in 30 days. Based on these gigs, the overall price performance for the year is -39.93%. The short interest in Kazia Therapeutics Limited ADR (NASDAQ:KZIA) is 47130.0 shares and it means that shorts have 0.23 day(s) to cover.
Kazia Therapeutics Limited ADR (KZIA) estimates and forecasts
Statistics show that Kazia Therapeutics Limited ADR has outperformed its competitors in share price, compared to the industry in which it operates. Kazia Therapeutics Limited ADR (KZIA) shares have gone up 56.51% during the last six months, with a year-to-date growth rate more than the industry average at 56.58% against 15.20.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 4.22%. While earnings are projected to return 91.72% in 2024.
KZIA Dividends
Kazia Therapeutics Limited ADR is due to release its next quarterly earnings in August. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Kazia Therapeutics Limited ADR (NASDAQ:KZIA)’s Major holders
The next largest institutional holding, with 63956.0 shares, is of HSBC HOLDINGS PLC’s that is approximately 0.0351% of outstanding shares. At the market price on 2024-03-31, these shares were valued at $20114.0.
